
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
B&L buys Pharmos piece; deal could hit $49 millionRochester, NY-Bausch & Lomb has acquired the rights to theloteprednol etabonate ophthalmic business of Pharmos Corp. for a price thatmight reach $49 million.




